Home » Stocks » BLCM

Bellicum Pharmaceuticals, Inc. (BLCM)

Stock Price: $3.09 USD 0.03 (0.98%)
Updated December 4, 4:00 PM EST - Market closed
After-hours: $3.11 +0.02 (0.65%) Dec 4, 7:55 PM

BLCM Stock Price Chart

Key Info

Market Cap 18.85M
Revenue (ttm) 5.13M
Net Income (ttm) -67.57M
Shares Out 5.06M
EPS (ttm) -11.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $3.09
Previous Close $3.06
Change ($) 0.03
Change (%) 0.98%
Day's Open 3.06
Day's Range 3.04 - 3.12
Day's Volume 291,941
52-Week Range 2.80 - 22.90

BLCM Stock News

Insider Monkey - 1 week ago

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking ...

Zacks Investment Research - 2 weeks ago

Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 2 weeks ago

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: CAH, FNF, GLUU, QLYS
GlobeNewsWire - 4 weeks ago

Strategic focus on clinical GoCAR-T ® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year

GlobeNewsWire - 1 month ago

HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the cl...

Market Watch - 1 month ago

Shares of Bellicum Pharmaceuticals Inc. plunged 35.1% in midday trading Friday, putting them on track for their biggest-ever one-day drop, after the clinical stage biopharmaceutical company sa...

GlobeNewsWire - 1 month ago

HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pr...

GlobeNewsWire - 1 month ago

HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interi...

GlobeNewsWire - 2 months ago

HOUSTON, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equit...

GlobeNewsWire - 2 months ago

HOUSTON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that ...

Seeking Alpha - 2 months ago

Bellicum Pharmaceuticals' stock continues to be pounded into submission by the market. Now that the market has obliterated any premium left in the stock, I am looking to accumulate.

GlobeNewsWire - 3 months ago

HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced tha...

Seeking Alpha - 3 months ago

Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 4 months ago

Management to host webcast and conference call on Thursday, August 6, 2020 at 5 p.m. ET / 2 p.m. PT Management to host webcast and conference call on Thursday, August 6, 2020 at 5 p.m. ET / ...

GlobeNewsWire - 5 months ago

HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clea...

Zacks Investment Research - 6 months ago

Top Ranked Momentum Stocks to Buy for June 1st

Other stocks mentioned: AGFS, BAND, FLWS
GlobeNewsWire - 6 months ago

HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the p...

Zacks Investment Research - 6 months ago

Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GlobeNewsWire - 7 months ago

HOUSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equ...

GlobeNewsWire - 7 months ago

Purchase price of $15 million from sale of manufacturing, office and laboratory facility

Seeking Alpha - 8 months ago

Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

HOUSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equi...

GlobeNewsWire - 9 months ago

HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”), a leader in developing novel, controllable cellular immunotherapies fo...

GlobeNewsWire - 10 months ago

HOUSTON, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited ...

GlobeNewsWire - 10 months ago

HOUSTON, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new ...

GlobeNewsWire - 10 months ago

Houston manufacturing facility and portions of Bellicum’s Technical Operations and Quality staff to be acquired by MD Anderson

GlobeNewsWire - 11 months ago

Bellicum’s proprietary technology licensed for use in CD19 CAR NK program Bellicum’s proprietary technology licensed for use in CD19 CAR NK program

GlobeNewsWire - 1 year ago

iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro

Seeking Alpha - 1 year ago

Bellicum Pharmaceuticals, Inc. (BLCM) CEO Rick Fair on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -1.75% and -65.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead...

Zacks Investment Research - 1 year ago

Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

HOUSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...

Seeking Alpha - 1 year ago

The stock has gained 20% since Baker Bros. disclosed its stake in the company.

Seeking Alpha - 1 year ago

Bellicum has produced some solid trial data for its lead therapy candidate BPX-501 in pediatric HSCT patients.

GlobeNewsWire - 1 year ago

HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited ...

GlobeNewsWire - 1 year ago

Closing of $57.5 Million Public Offering of Preferred Stock and Warrants and Receipt of $12.1 Million Option Fee Related to Private Placement of up to $70.0 Million of Preferred Stock and Warr...

Zacks Investment Research - 1 year ago

Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of -7.41% and 497.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for ...

Zacks Investment Research - 1 year ago

Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Bellicum recently publicized Rivo-cel hit the primary endpoint of event-free survival rate at 180 days of 90.9% in their BP-004 European registrational study.

Seeking Alpha - 1 year ago

Bellicum Pharmaceuticals recently reported promising data for BPX-601 at ASCO. The company's GoCAR-T program is taking aim at solid tumors and could be a leading therapy if approved.

Zacks Investment Research - 1 year ago

Bellicum Pharmaceuticals (BLCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of 1.79% and 158.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for ...

Benzinga - 1 year ago

Bellicum Pharmaceuticals, Inc. announces its next round of earnings this Tuesday, March 12.

About BLCM

Bellicum Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to t... [Read more...]

Industry
Biotechnology
IPO Date
Dec 18, 2014
CEO
Richard Fair
Employees
107
Stock Exchange
NASDAQ
Ticker Symbol
BLCM
Full Company Profile

Financial Performance

In 2019, BLCM's revenue was $7.14 million, an increase of 537.77% compared to the previous year's $1.12 million. Losses were -$112.48 million, 14.7% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for BLCM is 4.75, which is an increase of 53.72% from the latest price.

Price Target
$4.75
(53.72% upside)